hironori yoshida

Kyoto University Hospital
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Peripheral blood (PB) is a source of tumor-infiltrating tumor-reactive T cells (TR-T). Circulating TR-Ts (cTR-T) in PB are expected to contribute to the efficacy of immune checkpoint inhibitors (ICIs), but their phenotype remains poorly understood. Here we analyse paired tumor-infiltrating and peripheral CD8 + T cells from patients with non-small cell lung carcinoma (NSCLC), using single-cell RNA and T cell receptor (TCR) sequencing. Tumor-infiltrating TR-Ts are defined based on the reported TR-T-associated gene signatures. Using their TCR sequence as a barcode, we identify cTR-Ts and their specific surface markers, including CD49a, CD49b, and HLA-DR. Trajectory analysis assigns a progenitor-like phenotype to cTR-Ts, suggesting a potential developmental relationship with tumor-infiltrating TR-Ts. By single-cell transcriptomic and flow cytometric analysis on an ICI-treated cohort we show that pre-treatment cTR-Ts in responders are characterized by a relatively low expression of exhaustion-related CD38. Following the first dose, cTR-Ts of responders transit towards a TCF7 + stem-like phenotype. Additionally, we validate cTR-T’s phenotypic changes following PD-1 blockade therapy in mouse tumor models with artificial antigen. These findings suggest that the phenotypic state and transition of cTR-Ts may reflect their functional potential after tumor infiltration and are associated with therapeutic outcomes of ICIs.

Year:

2026

Brain metastases are frequent and often lethal complications of advanced cancers. Microglia, resident immune cells of the brain, are known to exert both anti-tumor and pro-tumor functions in late-stage metastases; however, their response during the initial outgrowth of metastatic lesions is not well characterized. Understanding how heterogeneous microglial subgroups are regulated in the developing tumor microenvironment could pave the way for therapeutic strategies to eliminate metastatic tumors at an early stage. In this study, we used a combination of in vivo fate map imaging, single-cell RNA sequencing, and a holographic photoconversion-based technique (Opto-omics) to track tumor fate and early microglial responses over time in the same animals during colonization of disseminated tumor cells. The microglial population was transcriptionally and morphologically heterogeneous, comprising both pro- and anti-tumor subsets. Genetic and pharmacological perturbations revealed that microglial phenotypes could be shifted by inhibiting TGF-β signaling or by deleting the tumor cell surface antigens CD24a and CD47. These findings reveal targetable plasticity in early-stage microglial responses to brain metastasis and suggest that harnessing pro-phagocytic microglial states may offer a therapeutic window before systemic immunosuppression becomes dominant.

Year:

2026

Year:

2026

Year:

2025

Year:

2025

The BRAF V600E mutation is observed in 2% of the patients with lung adenocarcinoma (LUAD), and combination therapy targeting BRAF and mitogen‐activated protein kinase (MEK) is the standard treatment for this population. However, acquired resistance inevitably develops, which highlights the need for novel therapeutic strategies. In this study, we established a patient‐derived BRAF V600E‐mutated LUAD cell line, KTOR81, and investigated the potential of targeting the Yes‐associated protein 1 (YAP1)/transcriptional enhanced associate domain 1 (TEAD1) pathway in combination with BRAF inhibition. We observed that the novel TEAD1 inhibitor VT103 enhanced the efficacy of the BRAF inhibitor dabrafenib in KTOR81 cells and xenograft models. The combination of dabrafenib and VT103 downregulated the expression of the antiapoptotic protein survivin, which is transcriptionally regulated by the YAP1/TEAD1 complex, leading to increased apoptosis. Moreover, we used a LUAD tissue microarray to compare the staining patterns of YAP1, TEAD1, and survivin, and examined their association with prognosis. These analyses revealed a strong correlation between YAP1, TEAD1, and survivin expression in LUAD, suggesting the relevance of the YAP1/TEAD1‐survivin axis beyond BRAF V600E‐mutated cases. While no statistically significant association was observed between survivin expression and prognosis, when limited to driver oncogene‐positive patients, high survivin expression was suggested to be associated with poor prognosis. These findings provide preclinical evidence for the efficacy of combining TEAD1 inhibition with BRAF‐targeted therapy in BRAF V600E‐mutated LUAD and highlight the YAP1/TEAD1‐survivin axis as a potential therapeutic target especially in the driver oncogene‐positive LUAD patients.

Year:

2025

Year:

2025

Purpose This study aims to clarify the relationship between rs2282055, a single-nucleotide polymorphism (SNP) in programmed death-ligand 1 (PD-L1), and TPS. Polcaro et al. (2024) showed that rs822336, a SNP in PD-L1, predicts the effect of immune checkpoint inhibitors (ICIs). However, the study did not show a relationship between rs822336 and the tumor proportion score (TPS), which is currently used as a primary marker. Therefore, we examined this relationship. Method Patients treated with immune checkpoint inhibitor monotherapy for non-small cell lung cancer at Kyoto University Hospital until January 2023, with TPS data and biological specimens available for SNP measurement, were eligible for this study. Genomic DNA was extracted from peripheral blood leukocytes. We used rs2282055, which is in linkage disequilibrium with rs822336, instead of rs822336, because of its distribution in the Asian patient population. We retrospectively extracted data on age, sex, smoking history, driver mutations, TPS, progression-free survival (PFS), and best response to ICI from medical records. Result The rs2282055 T/T genotype was associated with significantly better PFS in the TPS-negative population than in the other genotypes. In contrast, no differences were observed in TPS-positive patients. Conclusion The rs2282055 genotype may help in selecting cases from the TPS-negative patient population that may benefit from ICI therapy.

Year:

2025

Background Interstitial lung disease (ILD) is one of the most common fatal immune-related adverse events (irAEs). ILD development adversely affects the continuation of anticancer drug therapy, including immune checkpoint inhibitor (ICI) therapy and prognosis. There are no established useful clinical indicators for the early detection of ILD. Furthermore, the factors that lead the attending physician to suspect ICI-induced ILD (ICI-ILD) remain unclear. This study aimed to investigate the ICI-ILD detection based on subjective symptoms and their relationship with disease severity in patients receiving anti-PD-1/PD-L1 antibody. Methods This was a retrospective observational study. We enrolled the patients who received anti-PD-1/PD-L1 antibody at Kyoto University Hospital between September 2014 and April 2021. Patients who developed ICI-ILD were stratified into two distinct groups based on factors that triggered the suspicion of ILD development. The “Subjective symptoms” group was defined as patients in whom ILD was detected based on subjective symptoms. Conversely, the “Routine examinations” group was defined as patients in whom ILD was suspected based on scheduled routine examinations. The severity of ILD in each group was assessed and its association with changes in the respiratory symptoms was examined. Results Of 926 patients who received anti-PD-1/PD-L1 antibody, 51 patients (5.5%) developed ICI-ILD. The incidence of ICI-ILD in patients with lung cancer was significantly higher than that in patients with other cancers ( P < 0.001). Among the patients with ICI-ILD, 27 patients (52.9%) were classified into the “Subjective symptoms” group. The “Subjective symptoms” group exhibited a significantly higher proportion of Grade 3–5 ICI-ILD cases than the “Routine examinations” group (76.2% vs. 23.8%, P = 0.010). At the last visit, before the suspected onset of ILD, 21 of the 27 patients (77.8%) had no symptoms or no change in the respiratory symptoms. Conclusion Subjective symptoms triggered the suspicion of Grade 3–5 ICI-ILD. Enhanced monitoring and patient education could be essential for the early detection of ICI-ILD because ILD may develop rapidly. Our findings might help to manage ICI-ILD in clinical practice.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (13)

Kei IIDA

Lecturer

Kindai University

JAPAN
View details

Tomoko Funazo

Kyoto University Hospital

JAPAN
View details

Takashi Nomizo

Assistant Professor

Kyoto University Hospital

JAPAN
View details

Akihiko Yoshizawa

Kyoto University Hospital

JAPAN
View details

Masumi Hirabayashi

Associate Professor

National Institutes of Natural Sciences

JAPAN
View details

Hiroaki Ozasa

助教 / Assistant Professor

Kyoto University

JAPAN
View details

Takahiro Tsuji

Fred Hutch Cancer Center

UNITED STATES
View details

Hiroshi Date

Duke University Medical Center

UNITED STATES
View details

Kazutaka Hosoya

Medical Staff

Kyoto University Hospital

JAPAN
View details

Hiromu Yano

Assistant Professor (Tenure-track)

Kumamoto University

JAPAN
View details

Toyohiro Hirai

Kyoto University

JAPAN
View details

Toshi Menju

Associate Professor

Kyoto University

JAPAN
View details

Daisuke Sugiyama

Senior Lecturer

Nagoya University

JAPAN
View details